New large-scale clinical evidence suggests that incorporating symmetric dimethylarginine (SDMA) alongside traditional markers helps identify many more cases of early renal dysfunction that would otherwise be missed.

For many years, serum creatinine was the primary marker used in renal assessment in clinical chemistry panels. However, a significant loss of nephron function is required before creatinine exceeds the reference range. Additionally, creatinine is influenced by changes in lean body mass, which can further mask elevations.

  Kidney disease has an early warning system. Learn more about IDEXX SDMA testing.

SDMA is now widely used as an accurate indicator of kidney filtration, as it can detect kidney issues when as little as 25% to 40% of function is impaired. In addition to muscle loss, SDMA is not affected by a pet's age or weight, making it especially reliable for older or frail animals.

Why SDMA Matters

SDMA is an amino acid derived from arginine that is produced in the body at a steady rate and excreted exclusively by the kidneys. This makes it a reliable indirect marker of glomerular filtration rate (GFR). Unlike creatinine, SDMA is minimally influenced by lean body mass, offering a more consistent signal of renal filtration across patients of varying body conditions.

Peer-reviewed studies have demonstrated that SDMA begins to rise when approximately 25% to 40% of renal function is lost, compared to the roughly 75% loss required before creatinine exceeds its reference range. While the individual value of SDMA is well established, a critical clinical question remained: How often does SDMA identify patients with decreased renal function that creatinine alone would miss, and does this occur consistently across life stages?

Study Overview and Methods

Researchers conducted a retrospective analysis of diagnostic data generated by IDEXX in-practice platforms. The dataset included about 47,000 dogs and 46,000 cats, aged from 1 to 20 years, with samples collected between January 2021 and July 2022. By using real-world clinical data from routine diagnostic submissions, this study avoided the selection biases of hospital-based referral populations, providing insight into how renal biomarkers perform in real-world general practice populations.

The main approach was to evaluate, for each patient, whether creatinine alone, SDMA alone, or a combination of both biomarkers revealed renal function issues, indicated by values exceeding validated species-specific reference ranges in patients with dilute urine specific gravity. Animals were categorized by age and species to determine whether missed cases were concentrated in particular life stages or distributed across the population.

Key Findings

The results were clinically significant. Across both species, incorporating SDMA alongside creatinine in the chemistry profile identified approximately 30% more patients with decreased renal function than creatinine alone. In practical terms, this means that for every 10 patients with renal insufficiency, three would be missed entirely if the veterinarian relied solely on creatinine.

A significant finding was that missed cases were not limited to any specific demographic. Increased SDMA with normal creatinine was seen in young, adult, and senior groups, including both dogs and cats. The study highlights the importance of including SDMA in the diagnostic process for all age groups, even during wellness visits for apparently healthy young adults.

Clinical Implications

Early recognition of renal dysfunction enables veterinarians to recommend actionable next steps, such as:

• Investigating for underlying disease that may be impacting the kidneys.

• Scheduling focused renal disease recheck.

• Monitoring blood pressure.

• Checking urine specific gravity and proteinuria.

• Reviewing medications for nephrotoxic potential.

• Implementing targeted nutrition and dietary phosphorus restrictions when necessary.

These steps are much more effective when taken while there is still significant residual renal function. Waiting until creatinine exceeds the reference range may mean waiting until 75% of nephron function is already lost.

The practical recommendation from this evidence is clear: Standard practice with routine chemistry panels should include SDMA alongside creatinine; it should not be reactive as an add-on for patients already suspected of having kidney disease. The value of SDMA is greatest in patients who appear clinically normal, where creatinine within reference intervals provides false reassurance.

Annual wellness blood work, pre-anesthetic panels, and monitoring profiles in patients with concurrent conditions such as diabetes, hyperthyroidism, or hypertension should all include SDMA to ensure that renal changes are not overlooked.

Detecting kidney disease earlier is not just about better diagnostics; it’s about giving patients the best chance for quality of life and longevity.

Tags: SDMA, renal health,